- MaxWell Biocorporation Wins Presidential Support for Faster Registration
of Modern Medicines in Ukraine -
WASHINGTON, Sept. 30 /PRNewswire/ -- Dr. Kenneth Alibek, President and CEO of MaxWell Biocorporation, LLC, and Dr. Peter M. Leitner, President of MaxWell USA, LLC, participated today in a presidential breakfast to honor Ukrainian President Victor Yushchenko.
The breakfast was hosted by the U.S.-Ukraine Business Council (USUBC). Nearly 100 senior business leaders, academics, and diplomats attended this invitation-only event, including three former United States ambassadors to Ukraine and the current US Ambassador to Kyiv William Taylor.
President Yushchenko discussed the current political and economic situation in Ukraine. The President repeated his strong support for Ukraine's further integration into the Euro-Atlantic community as shown by the recent events in Georgia, spoke about Ukraine's business environment, thanked the U.S. companies for their investments in Ukraine, and urged American investors to participate in even more projects in Ukraine.
Asking the first question, Dr. Alibek asked the Ukrainian President about prospects for ensuring timely registration and licensing procedures for foreign pharmaceutical companies with established production facilities in Ukraine, in order to expedite access to the latest medicines for the people of Ukraine. Companies are experiencing unnecessary and costly delays in this area, Dr. Alibek noted.
President Yushchenko stated that it is very important for Ukraine to have the latest and most effective pharmaceuticals. The Ukrainian President promised he would monitor this situation, and suggested to Dr. Alibek that he work closely with Mr. Yushchenko's staff to resolve this issue.
Later the same day, President Yushchenko met with President Bush at the White House, spoke at the National Press Club, and laid a wreath at the monument to famous Ukrainian poet Taras Shevchenko in Washington, DC.
MaxWell Biocorporation (http://www.max-well.com) is a U.S.-based,
privately-held international medical and pharmaceutical company with wholly
owned subsidiaries and affiliates in the United States and Ukraine
dedicated to increasing life expectancy and improving the quality of life
of people in Ukraine and other underserved emerging healthcare markets in
the former Soviet Union. MaxWell targets oncological, cardiological,
chronic infectious and autoimmune disorders and diseases through the
development, production, and introduction into clinical practice of
sophisticated, high quality, and affordable off-patent generic
biopharmaceutical and chemopharmaceutical medicines and the latest
diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."
"We Help You Live Longer"
202-454-3403 Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Kenneth Alibek https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78826 Peter Leitner https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78827
|SOURCE MaxWell Biocorporation|
Copyright©2008 PR Newswire.
All rights reserved